Literature DB >> 9160489

Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event.

Q H Li1, S W Lagakos.   

Abstract

We consider application of the Wei-Lin-Weissfeld (WLW) method for multiple failure time data when analysing a disease process consisting of a recurring outcome, such as clinical progression, and a terminating outcome, such as death. In order to adapt WLW for this situation, 'events' must be specified that define multiple failure times and whether these are censored. Various choices of events are possible, and each corresponds to inferences about a different aspect of the underlying disease process. Definitions which regard the terminating outcome as a censor of the recurring outcome focus on specific cause-specific hazard functions, while event definitions which make no distinction between a recurring and terminating outcome focus on hazard functions of the induced failure times. Some event definitions require strong statistical assumptions to yield valid inferences and are not recommended. The application of WLW for recurring/terminating processes is illustrated with the results of two recently conducted clinical trials in persons with HIV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160489     DOI: 10.1002/(sici)1097-0258(19970430)16:8<925::aid-sim545>3.0.co;2-2

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  Marginal means/rates models for multiple type recurrent event data.

Authors:  Jianwen Cai; Douglas E Schaubel
Journal:  Lifetime Data Anal       Date:  2004-06       Impact factor: 1.588

2.  Time-varying coefficients in a multivariate frailty model: Application to breast cancer recurrences of several types and death.

Authors:  Yassin Mazroui; Audrey Mauguen; Simone Mathoulin-Pélissier; Gaetan MacGrogan; Véronique Brouste; Virginie Rondeau
Journal:  Lifetime Data Anal       Date:  2015-05-06       Impact factor: 1.588

3.  Body fat distribution and incident cardiovascular disease in obese adults.

Authors:  Ian J Neeland; Aslan T Turer; Colby R Ayers; Jarett D Berry; Anand Rohatgi; Sandeep R Das; Amit Khera; Gloria L Vega; Darren K McGuire; Scott M Grundy; James A de Lemos
Journal:  J Am Coll Cardiol       Date:  2015-05-19       Impact factor: 24.094

4.  Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.

Authors:  Brian Claggett; Lu Tian; Davide Castagno; Lee-Jen Wei
Journal:  Biostatistics       Date:  2014-08-12       Impact factor: 5.899

5.  Multiple event times in the presence of informative censoring: modeling and analysis by copulas.

Authors:  Dongdong Li; X Joan Hu; Mary L McBride; John J Spinelli
Journal:  Lifetime Data Anal       Date:  2019-11-15       Impact factor: 1.588

6.  Analysis of multi-stage treatments for recurrent diseases.

Authors:  Xuelin Huang; Jing Ning
Journal:  Stat Med       Date:  2012-07-24       Impact factor: 2.373

7.  Infection-related hospitalizations in older patients with ESRD.

Authors:  Lorien S Dalrymple; Kirsten L Johansen; Glenn M Chertow; Su-Chun Cheng; Barbara Grimes; Ellen B Gold; George A Kaysen
Journal:  Am J Kidney Dis       Date:  2010-07-08       Impact factor: 8.860

8.  Does intention to recommend HPV vaccines impact HPV vaccination rates?

Authors:  Kristen A Feemster; Maria Middleton; Alexander G Fiks; Sarah Winters; Sara B Kinsman; Jessica A Kahn
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

9.  Flexible estimation of differences in treatment-specific recurrent event means in the presence of a terminating event.

Authors:  Qing Pan; Douglas E Schaubel
Journal:  Biometrics       Date:  2008-11-13       Impact factor: 2.571

10.  Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study.

Authors:  Jisheng Cui; Andrew Forbes; Adrienne Kirby; Ian Marschner; John Simes; David Hunt; Malcolm West; Andrew Tonkin
Journal:  BMC Med Res Methodol       Date:  2010-04-01       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.